Abcuro, Inc. news

Abcuro, a leading biotechnology company focused on immunology therapeutics, announced the completion of a $8M Series A financing round.  Partners Innovation Fund, Kaitai Capital, and ShangPharma Innovation all contributed to the round.  The proceeds from this financing will be used to advance the preclinical development of Abcuro’s programs in autoimmunity and immuno-oncology.

Abcuro is developing novel first in class therapeutics in immunology.  Clinician founder